Neogen Chemicals Limited has announced its financial performance for the quarter and financial year ended March 31, 2026. The company reported a standalone profit of ₹46.96 crore and consolidated profit of ₹28.75 crore for the full fiscal year. Additionally, the Board has recommended a final dividend of Re. 1 per equity share and disclosed updates on major capital projects at its subsidiary, Neogen Ionics Limited.
Financial Highlights
For the financial year ended March 31, 2026, Neogen Chemicals Limited achieved a standalone revenue from operations of ₹855.49 crore compared to ₹773.65 crore in the previous year. The standalone profit for the year stood at ₹46.96 crore. On a consolidated basis, the company reported a total revenue of ₹861.96 crore and a profit for the period of ₹28.75 crore.
Dividend Recommendation
The Board of Directors has recommended a final dividend of Re. 1 per equity share for the financial year 2025-26. This recommendation is subject to the approval of shareholders at the company’s upcoming 37th Annual General Meeting.
Capital Project Updates
Neogen Ionics Limited, a wholly owned subsidiary, has provided updates regarding the projected costs and timelines for its ongoing projects. The Dahej Phase 1 project is now expected by February 2027 with a projected cost of ₹428 crore. The Pakhajan Phase 2 project is scheduled for March 2027 with a projected cost of ₹1,367 crore. The total cost for these projects is estimated at ₹1,795 crore, with funding secured through promoter equity infusion and planned contributions from a joint venture partner.
Corporate Developments
The company also noted recent governance enhancements, including amendments to its Code for Prevention of Insider Trading. Additionally, the company highlighted recent employee stock option grants and the successful preferential allotment of shares to a promoter group member, Cadamba Solutions Private Limited, completed in April 2026.
Source: BSE
